SG10202105118WA - Compositions and methods for the treatment of fungal infections - Google Patents

Compositions and methods for the treatment of fungal infections

Info

Publication number
SG10202105118WA
SG10202105118WA SG10202105118WA SG10202105118WA SG10202105118WA SG 10202105118W A SG10202105118W A SG 10202105118WA SG 10202105118W A SG10202105118W A SG 10202105118WA SG 10202105118W A SG10202105118W A SG 10202105118WA SG 10202105118W A SG10202105118W A SG 10202105118WA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
fungal infections
fungal
Prior art date
Application number
SG10202105118WA
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG10202105118WA publication Critical patent/SG10202105118WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/21—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/62—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
SG10202105118WA 2016-11-28 2017-11-24 Compositions and methods for the treatment of fungal infections SG10202105118WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641040639 2016-11-28
IN201741012687 2017-04-07

Publications (1)

Publication Number Publication Date
SG10202105118WA true SG10202105118WA (en) 2021-06-29

Family

ID=61003288

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202105118WA SG10202105118WA (en) 2016-11-28 2017-11-24 Compositions and methods for the treatment of fungal infections

Country Status (15)

Country Link
US (4) US11312707B2 (es)
EP (3) EP3581566A3 (es)
JP (3) JP7176760B2 (es)
KR (3) KR102406424B1 (es)
CN (1) CN110198929A (es)
AU (3) AU2017365111C1 (es)
BR (1) BR112019010816A2 (es)
CA (1) CA3044755A1 (es)
IL (3) IL287621B (es)
MX (2) MX2019006164A (es)
NZ (2) NZ785293A (es)
RU (2) RU2019119089A (es)
SG (1) SG10202105118WA (es)
WO (1) WO2018096497A1 (es)
ZA (1) ZA201903571B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003354A4 (en) * 2019-07-31 2023-11-15 The Regents Of The University Of Michigan POSACONAZOLE COCRYSTALS, METHODS OF MANUFACTURE AND USE THEREOF
WO2022190030A1 (en) * 2021-03-10 2022-09-15 Avaca Pharma Private Limited A topical formulation for the treatment of skin diseases
WO2023073574A1 (en) * 2021-10-28 2023-05-04 Cellix Bio Private Limited Process for the preparation of piperidine carboxamides salt forms and thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
JPH0676285B2 (ja) * 1985-11-01 1994-09-28 三井東圧化学株式会社 ベンジルアミン誘導体、その製造法およびその用途
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
GB2208598A (en) * 1987-08-15 1989-04-12 Ciba Geigy Ag Antimicrobial preparations for external use
EP0363326A3 (en) * 1988-10-07 1991-10-09 Sandoz Ag Fungicidal amines
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
RU2189982C2 (ru) * 1997-03-31 2002-09-27 Такеда Кемикал Индастриз, Лтд. Азольные соединения, способ их получения, противогрибковая фармацевтическая композиция и способ лечения грибковой инфекции
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
WO2000007574A1 (de) * 1998-08-06 2000-02-17 Schierholz Joerg Medizinprodukte mit retardierter pharmakologischer aktivität und verfahren zu ihrer herstellung
WO2003101392A2 (en) * 2002-05-31 2003-12-11 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
EP1718640A4 (en) * 2004-02-26 2008-01-09 Transform Pharmaceuticals Inc NEW CRYSTALLINE FORMS OF CONAZOLES AND METHOD FOR THEIR PREPARATION AND APPLICATION
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8258164B2 (en) * 2006-09-12 2012-09-04 Curatek Pharmaceuticals Holding, Inc. Nitroimidazole composition and method
US20090068287A1 (en) * 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US9314524B2 (en) 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
CN102770123A (zh) 2009-12-23 2012-11-07 纽沃研究股份有限公司 用于治疗甲癣的高渗透性特比萘芬制剂
CN103857440B (zh) 2011-06-22 2018-09-25 维奥姆生物科学有限公司 基于缀合物的抗真菌和抗细菌前药
AU2014276460A1 (en) 2013-06-04 2015-12-24 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
EP4019506A1 (en) * 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
WO2015116947A1 (en) * 2014-02-01 2015-08-06 University Of Connecticut Itraconazole analogues and methods of use thereof
US9468606B2 (en) 2014-03-31 2016-10-18 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of an acidic benefit agent
EP3201168B1 (en) * 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CN105193808A (zh) * 2015-10-14 2015-12-30 南京邮电大学 Bdsf与伊曲康唑联用对临床耐药白念珠菌的协同药效
CN106008470A (zh) * 2016-05-30 2016-10-12 齐鲁工业大学 系列伏立康唑盐的合成及其合成方法
BR112019010809A2 (pt) * 2016-11-28 2019-10-01 Cellix Bio Private Ltd composto de fórmula i, composto de fórmula ii, composto de fórmula iii, composto de fórmula iv, composto de fórmula v, composto de fórmula vi, composto de fórmula vii, composto de fórmula viii, composto de fórmula ix, composto de fórmula x, composto de fórmula xi, composto de fórmula xii, e composição farmacêutica

Also Published As

Publication number Publication date
EP3538514A1 (en) 2019-09-18
JP7176760B2 (ja) 2022-11-22
EP3581566A2 (en) 2019-12-18
US20210053950A1 (en) 2021-02-25
AU2022201182B2 (en) 2022-08-11
CN110198929A (zh) 2019-09-03
ZA201903571B (en) 2021-09-29
JP2023011847A (ja) 2023-01-24
US20220213073A1 (en) 2022-07-07
US20200361912A1 (en) 2020-11-19
IL266927B (en) 2021-12-01
AU2017365111A1 (en) 2019-06-20
KR20220080202A (ko) 2022-06-14
WO2018096497A1 (en) 2018-05-31
AU2022201182A1 (en) 2022-03-17
KR102567089B1 (ko) 2023-08-17
AU2022201181A1 (en) 2022-03-17
KR102406424B1 (ko) 2022-06-08
JP2019535793A (ja) 2019-12-12
RU2021117584A (ru) 2021-09-08
AU2017365111B2 (en) 2022-02-17
IL266927A (en) 2019-08-29
IL287621A (en) 2021-12-01
MX2019006164A (es) 2019-11-28
EP4230619A1 (en) 2023-08-23
KR20190087547A (ko) 2019-07-24
EP3581566A3 (en) 2020-01-22
US11220493B2 (en) 2022-01-11
RU2019119089A3 (es) 2021-04-14
IL287622B (en) 2022-07-01
NZ785293A (en) 2023-09-29
US11485730B2 (en) 2022-11-01
US11312707B2 (en) 2022-04-26
KR20220080203A (ko) 2022-06-14
BR112019010816A2 (pt) 2019-10-01
US20220340551A1 (en) 2022-10-27
AU2017365111C1 (en) 2022-05-26
CA3044755A1 (en) 2018-05-31
IL287621B (en) 2022-07-01
IL287622A (en) 2021-12-01
NZ754155A (en) 2022-07-01
RU2019119089A (ru) 2020-12-21
JP2023011846A (ja) 2023-01-24
KR102567090B1 (ko) 2023-08-17
AU2022201181B2 (en) 2022-08-25
MX2022005523A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
EP3347469A4 (en) METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA
EP3408344A4 (en) METHOD AND COMPOSITIONS FOR BORING TREATMENT
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3651801A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF MUSHROOM INFECTION
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
HK1249515A1 (zh) 預防和治療聽力損失的方法和組合物
IL287622A (en) Preparations and methods for treating fungal infections
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
IL291266A (en) Preparations and methods for treating infections
EP3429584A4 (en) COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA
EP3426671A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
ZA201808232B (en) Compositions and methods for the treatment of cancer
EP3368048A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DOSE
ZA201900984B (en) Methods and compositions for the treatment of warts
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
EP3258908A4 (en) Compositions and methods for treatment of skin infections
ZA202006569B (en) Methods of treating fungal infections
GB201621737D0 (en) Compositions and methods of treatment
EP3554494A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
EP3362085A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING MUCIN
EP3294339A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS
GB201605127D0 (en) Composition and methods of treatment
EP3436078A4 (en) METHOD AND COMPOSITIONS FOR TREATING ALS